6th Annual MSL Best Practices

As the regulatory environment related to industry-thought leader communications is becoming increasingly restrictive, the value of the Medical Science Liaison position continues to grow in importance and demand. While the MSL role is changing as a growing number of institutions and states are placing new limitations on thought leader and industry relationships, there is a reinvigorated focus on the exchange of highly scientific information. As products grow in complexity and competition intensifies, MSLs’ therapeutic area expertise, business acumen and relationship building skills are increasingly pivotal to the long-term success of their companies. Although faced with significant challenges in such a dynamic position and industry, through thoughtful, efficient and strategic communications, MSLs are poised to provide significant value to the KOL, company and industry as a whole.

Now in its sixth year, ExL Pharma’s 6th MSL Best Practices conference provides practical strategies related to the most significant issues affecting MSLs today. We are pleased to present you with expert-led sessions and time for discussion with some of the most experienced and knowledgeable leaders in the industry.

We look forward to greeting you in Virginia!

Highlights Include:

KEY OPINION LEADER DEVELOPMENT

Understanding KOLs’ Communication Preferences and Interests to Better Initiate and Maintain Successful Relationships

Carol Fier, Senior Regional Medical Liaison, Oncology, Scientific Affairs, Global Development, AMGEN

Steve Thuillier, Director of RML Planning and Operations, AMGEN

DEFINING THE ROLE OF THE MSL

Characterizing the MSL Position in a Time of Industry Shifts to Ensure Continued Value to Internal and External Stakeholders

Elizabeth Kupferer, PhD, Medical Liaison II, BAYER HEALTHCARE

MAXIMIZING THOUGHT LEADER INTERACTIONS

Engaging in Successful and Compliant Exchanges with KOLs in the Face of Significant Challenges

Douglas Young, PhD, Vice President, Americas Field Medical Science Center of Excellence, BRISTOL-MYERS SQUIBB

PANEL DISCUSSION: OFF-LABEL INFORMATION DISSEMINATION

Minimizing Risk in Off-Label Discussions and Ensuring that Conversations are Educational and Not Promotional

Gary Ellenor, Senior Medical Director, Neuroscience, PFIZER

David R. Rutledge, PharmD, Director, Worldwide Clinical Affairs, ABBOTT

Michael DeGeorge, PharmD, Regional Director, Medical Liaisons, KING PHARMACEUTICALS

 Gain take home strategies on the following topics:

-       KOL Development

-       MSL Performance Evaluation

-       Career Development

-       Regulatory Information and Updates

-       Off-Label Information Dissemination

-       Time Management

-       Maximizing Thought Leader Interactions

-       Value of Internal Partnerships

-       MSLs Supporting Clinical Research

-       Changing Nature of the KOL

-       Defining the Current and Future Role of the MSL

-       MSLs and Corporate Strategy

-       Diminishing Advisory Board Participation

-       Global KOLs

-       Competitive Intelligence

With Speakers from the Following Leading Companies:

ABBOTT

ACTELION

AMGEN

BAYER

BRISTOL-MYERS SQUIBB

HEALTHCARE

GENZYME

KING

MEDTRONIC

PFIZER

SHIRE

UCB

THOMPSON HINE

and more!